Merck and Co Inc (MRK) - Pharmaceuticals and Healthcare - Deals and Alliances Profile

Summary

Merck & Co Inc (Merck) is a biopharmaceutical company that focuses on the discovery, development, manufacture and commercialization of prescription medicines, biologic therapies, vaccines and animal health products. It offers prescription products for treating cardiovascular, cancer, immune disorders, infectious, respiratory and womens diseases, and diabetes. The company provides animal health products including vaccines, poultry products, livestock products and aquaculture products. Merck sells medicines to drug wholesalers, retailers, hospitals, government agencies and managed health care providers; and animal health products to veterinarians, distributors and animal producers. Outside the US, the company operates through subsidiaries. It operates in the Americas, Europe, the Middle East, Africa, Asia Pacific, and Latin America. Merck is known as MSD outside the US and Canada and is headquartered in Kenilworth, New Jersey, the US.

Merck & Co Inc (MRK) - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the companys Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

It derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals - Analysis of the companys financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals - Information on the companys major financial deals. Each such deal has a brief Summary, deal type, deal rationale; and deal financials and target Companys (major public companies) key financial metrics and ratios.
- Business Description - A brief description of the companys operations.
- Key Employees - A list of the key executives of the company.
- Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors - A list of the key competitors of the company.
- Key Recent Developments - A brief on recent news about the company.

Reasons to Buy

Get detailed information on the companys financial deals that enable you to understand the companys expansion/divestiture and fund requirements
- The profile enables you to analyze the companys financial deals by region, by year, by business segments and by type, for a five year period.

Understand the companys business segments expansion / divestiture strategy
- The profile presents deals from the companys core business segments perspective to help you understand its corporate strategy.

Access elaborate information on the companys recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a Summary of each deal, deal type, deal rationale, deal financials and Target Companys key financial metrics and ratios.

Equip yourself with detailed information about the companys operations to identify potential customers and suppliers.
- The profile analyzes the companys business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.



List of Tables 10
List of Figures 14
Merck & Co Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 15
Merck & Co Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 16
Merck & Co Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 17
Merck & Co Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 18
Merck & Co Inc, Medical Devices Deals, 2012 to YTD 2018 20
Merck & Co Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 21
Merck & Co Inc, Pharmaceuticals & Healthcare, Deal Details 34
Asset Purchase 34
Hypermarcas To Sell Rights To Manufacture Medicines To MSD Brazil Investments For US$31 Million 34
Venture Financing 35
Moderna Therapeutics Raises USD125 Million in Series H Preferred Equity Financing 35
Just Biotherapeutics Raises USD14 Million in Series A2 Financing 36
Just Biotherapeutics Raises USD15 Million in Series A Financing Round 38
RaNA Therapeutics Raises USD55 Million in series B Financing 39
Afferent Pharma Raises USD55 Million in Series C Financing 40
Gladius Pharma Raises USD3.3 Million in Series A Financing 41
NGM Biopharma Raises USD106 Million in Series E Financing 42
EnGene Raises USD11 Million in Series B Venture Financing 43
OsteoQC Raises Funds in Venture Financing 44
AdvanDx Raises US$12 Million In Series B-1 Venture Financing 45
HTG Molecular Diagnostics Raises Funds Through Extended Series E Financing 46
OncoEthix Raises US$19 Million In Series B Financing 47
Aviir Raises US$20 Million In Venture Financing 49
Afferent Pharmaceuticals Secures USD5 Million in Venture Funding Round 51
cCAM Biotherapeutics Raises US$6 Million In Series A Financing 52
Afferent Pharmaceuticals Secures USD5 Million in Venture Funding 53
Partnerships 54
Antigen Express Enters into Agreement with Merck for KEYTRUDA 54
CogState Enters Into Licensing Agreement With Merck Canada For Cognition Test 55
4D pharma Enters into Agreement with Merck 56
MSD Enters into Distribution Agreement with Kyorin Pharma 57
IO Biotech Enters into Clinical Trial Collaboration Agreement with Merck 58
Immutep Enters into Clinical Trial Collaboration and Supply Agreement with Merck 59
Eisai Enters into Co-Development and Co-Commercialization Agreement with Merck 60
Merck to Enter into Agreement with Schneider Electric 61
PharmAbcine Enters into Agreement with Merck 62
Parkinsons Institute and Clinical Center Enters into Agreement with Merck 63
Grunenthal Enters into Distribution Agreement with Merck 64
Astellas Pharma Enters into Co-Promotion Agreement with MSD 65
Aeglea BioTherapeutics Enters into Agreement with Merck 66
SELLAS Life Sciences Enters into Clinical Trial Agreement with Merck 67
Eisai Enters into Agreement with Merck for Eribulin 68
Eisai Enters into Agreement with Merck 69
AstraZeneca Enters into Agreement with Merck 70
Invenra Enters into Agreement With Merck 71
PDS Biotech Enters into Agreement with Merck 72
Leap Therapeutics Enters into Agreement with Merck International 73
Aduro Biotech Expands Agreement with Merck 74
OncoSec Medical Enters into Agreement with Merck Sharp & Dohme 75
Array BioPharma Enters into Agreement with Merck 76
Atara Biotherapeutics Enters into Agreement with Merck 77
HitGen Enters into Agreement with Merck 78
BerGenBio Enters into Agreement with Merck 79
Stratophase Enters into Agreement with Merck 80
CMIC Enters into Agreement with MSD for Diazoxide 81
Ramot at Tel Aviv University Enters into Research Agreement with Merck 82
NOXXON Pharma Enters into Agreement with Merck 83
Natrix Separations Enters into Co-Development Agreement with Merck and Sanofi 84
Proteros biostructures Enters into Agreement with Merck Sharp & Dohme 85
Genexine Enters into Clinical Research Agreement with Merck 86
Adaptimmune Therapeutics Enters into Clinical Trial Agreement with Merck for Keytruda 87
Merck Sharp & Dohme, Verastem and Cancer Research UK Enter into Agreement 88
Merck Enters into Distribution Agreement with JenKem Tech 89
MSD Enters into Agreement with Kyorin Pharma 90
Agency for Science, Technology and Research Enters into Agreement with Merck 91
Menarini Asia-Pacific Enters into Agreement with Merck 92
Innovative Targeting Solutions Enters into Research Agreement with Merck 93
Fujifilm Diosynth Biotech Partners with Merck 94
Merck Enters into Co-Promotion Agreement with Taiho Pharma for Pembrolizumab 95
Myriad Genetics Enters into Research Agreement with Tesaro and Merck 96
Daiichi Sankyo Enters into Co-Marketing Agreement with Merck 97
ImmunoGen Enters into Research Agreement with Merck 98
Merck Enters into Agreement with AbCellera Biologics 99
Affimed Enters into Research Agreement with Merck 100
BioLineRx Enters into Agreement with Merck 101
Quartet Medicine Enters into Agreement with Merck 102
Complix Expands Agreement with Merck 103
Eli Lilly Expands its Agreement with Merck 104
Merck Enters into Agreement with Akeso Biopharma 105
Amgen and Merck Enter into Agreement 106
Viralytics Enters into Agreement with Merck 107
GlaxoSmithKline Partners with Merck 108
Synthace Enters into Agreement with Merck 109
MacroGenics Enters into Agreement with Merck 110
Incyte Extends Partnership with Merck 111
Proteros Enters Into an Agreement with Merck Sharp and Dohme 112
Merck Enters into Agreement with OBI Pharma 113
Merck Enters into Agreement with DNAtrix 114
Merck Enters into Research Agreement with University of Texas MD Anderson Cancer Center 115
Immune Design Enters into Clinical Collaboration Agreement with Merck 116
Laboratorios Farmaceuticos Rovi Enters into Co-Marketing Agreement with Merck Sharp & Dohme for Orvatez 117
Plexxikon Enters into Agreement with Merck 118
PeptiDream Enters into Peptide Discovery Agreement with Merck 119
Organovo Enters into Research Agreement with Merck Sharp & Dohme 120
Syndax Pharma Expands its Agreement with Merck 121
Ablynx Extends Agreement with Merck to Develop Therapeutic Nanobody Candidates 122
NGM Biopharma Enters into R&D Agreement with Merck for Novel Biologic Therapeutics 123
Merck Expands Agreement with Eli Lilly 124
Enumeral Biomedical Amends Agreement with Merck Sharp & Dohme 125
Kyorin Pharma Amends Co-Marketing Agreement with MSD 126
Bind Therapeutics Enters into R&D Agreement with Merck 127
Advaxis Enters into Agreement with Merck 128
Bayer Enters Into Agreement With Merck For Soluble Guanylate Cyclase Modulators 129
Ferring Pharma And Merck Enter Into Agreement With World Health Organization For Anti-Bleeding Drug 130
Merck Enters Into Co-Development Agreement With Samsung Bioepis For MK-1293 131
Hanmi Pharma Enters into Co-promotion Agreement with Merck Sharp & Dohme Korea 132
Dako Enters Into Co-Development Agreement With Merck 133
Astellas Pharma Enters Into Co-Promotion Agreement With MSD For Ipragliflozin 134
Avanir Pharma Enters Into Agreement With Merck To Promote Diabetes Drugs 135
Optimer Pharma Extends Co-Promotion Agreement With Cubist Pharma For Dificid 137
Abide Therapeutics Enters Into Co-Development Agreement With Merck 138
Merck Enters Into Co-Development Agreement With Pfizer For Ertugliflozin 139
Cardiome Pharma Enters Into Co-Marketing Agreement With Merck For Brinavess 140
Lycera Enters Into Research Agreement With Merck To Develop Novel Treatments For Autoimmune Diseases 141
Adimab Expands Collaboration With Merck To Discover Human Antibody Candidates 142
Heptares Enters Into Research Agreement With Cubist Pharma For New Medicines Targeting GPCRs 143
ActoGeniX Enters Into Research Agreement With Merck 144
TPP Global Development Enters Into Agreement With Sprint Biosciences To Develop Choline Kinase Inhibitors 145
Ablynx Enters Into Agreement With Merck To Develop Therapeutic Nanobody Candidates 146
ALK Enters Into Co-Promotion Agreement With MSD For Grazax 147
Redbiotec Extends Drug Discovery Agreement With Merck 149
Merck Forms Joint Venture With Supera Farma Laboratorios 150
MSD Enters Into Distribution Agreement With Julphar 151
AstraZeneca Amends Co-Development Agreement With Merck For Nexium And Prilosec 152
Fundacion Medina Enters Into Research Agreement With Cubist Pharma 153
Trevena Enters Into Research Agreement With Merck For Biased Ligand Molecules 154
MSD India Plans Co-Marketing Agreement For Diabetes Drugs 155
Licensing Agreements 156
Prokaryotics Enters into Licensing Agreement with Merck 156
Merck Enters into Licensing Agreement with Institute of Cancer Research and Cancer Research UK 157
Merck Enters into Licensing Agreement with Cue Biopharma 158
Dongwha Pharm Enters into Licensing Agreement with Merck 159
Merck Enters into Licensing And Option Agreement with AIMM Therapeutics 160
Urovant Sciences Enters into Licensing Agreement with Merck Sharp & Dohme 161
Merck Enters into Licensing Agreement with Teijin Pharma 162
Kyorin Pharma Enters into Licensing Agreement with Merck 163
Merck Enters into Licensing Agreement with Bristol-Myers Squibb and Ono Pharma 164
Merck Expands Licensing Agreement with Moderna Therapeutics 166
Merck Enters into Licensing Agreement with Harvard University 168
Merck Enters into Licensing Agreement with AureoGen Biosciences 169
Merck Enters into Licensing Agreement with Cancer Research Technology 170
Adimab Enters into Licensing Agreement with Merck 171
Merck Enters into Licensing Agreement with Selvita 172
Merck Enters into Licensing Agreement with Codexis for CodeEvolver Platform Technology 173
Allergan Enters into Licensing Agreement with Merck 175
Merck Extends Licensing Agreement with Agenus 176
Arvinas Enters into Licensing Agreement with Merck 177
Moderna Therapeutics Amends Terms of Licensing Agreement with Merck 178
Merck Enters into Licensing Agreement with BioNovion 179
Zymeworks Extends Licensing Agreement with Merck 180
Merck Enters into Licensing Agreement with NewLink Genetics 181
Euroscreen Enters into Licensing Agreement with Merck 183
Sun Pharma Enters into Licensing Agreement with Merck 184
Kyorin Pharma Enters into Licensing Agreement with Merck 185
Bionomics Enters into Licensing Agreement with Merck for BNC375 186
Agenus Enters into Licensing Agreement with Merck for Checkpoint Antibody-based Cancer Immunotherapies 187
Gulf Pharma Enters into Licensing Agreement with MSD 188
Gulf Pharmaceutical Industries (Julphar) Enters into Licensing Agreement with Merck 189
NanoBio Enters Into Licensing Agreement With Merck 190
Merck Expands Licensing Agreement with Ablynx 191
ARMO Biosciences Enters into Licensing Agreement with Merck 193
Bionomics Extends Licensing Agreement with Merck 194
Xencor Enters Into Licensing Agreement With Merck 195
Cerecor Enters Into Licensing Agreement With Merck For MK-0657 196
Meiji Seika Pharma Enters into Licensing Agreement with MSD 197
Merck Enters into Licensing Agreement with Ra Pharma 198
Cubist Pharma Enters Into Licensing Agreement With Astellas Pharma For Ceftolozane 200
Microbiotix Enters Into Licensing Agreement With Merck For MBX-700 And MBX-701 201
Menlo Therapeutics Enters into Licensing Agreement with Merck 202
Merck Enters Into Licensing Agreement With GE Healthcare For Flutemetamol 203
Theravance Enters Into Licensing Agreement With Merck For Cardiovascular Therapeutic Candidates 204
Merck Enters Into Licensing Agreement With AiCuris For Investigational Portfolio Targeting Human Cytomegalovirus 205
MultiVir Enters into Licensing Agreement with Merck Sharp & Dohme 207
R-Pharm Enters Into Licensing Agreement With Merck For Narlaprevir 208
Ambrx Enters Into Licensing Agreement With Merck For Site Specific Protein Medicinal Chemistry Technology 209
Tesaro Enters Into Licensing Agreement With Merck Sharp & Dohme For Cancer Drug 210
Merck Enters into Licensing Agreement with Medicines Patent Pool 211
EnWave Enters into Licensing Agreement with Merck 212
Cipla Enters Into Licensing Agreement With MSD Pharma For Raltegravir 213
Polyplus-transfection Enters Into Licensing Agreement With Merck 215
AstraZeneca Enters Into Licensing Agreement With Merck For MK-1775 216
Merck Enters Into Licensing Agreement With Lupin 218
Hawaii Biotech Enters Into Licensing Agreement With Merck For West Nile Vaccine Technology 219
Acerta Pharma Enters into Licensing Agreement with Merck Sharp & Dohme 220
Netherlands Translational Research Center Enters Into Licensing Agreement With Merck 221
Delphi Genetics Enters Into Licensing Agreement With Merck For StabyExpress Technology 222
Merck Enters Into Licensing Agreement With Yamasa For EFdA 223
Merck Enters Into Licensing Agreement With Numerate For In Silico Drug Design Technology 224
Merck Extends Licensing Agreement with Codexis 225
Merck Enters Into Licensing Agreement With Protein Sciences For expresSF+ Insect Cell Technology 226
Equity Offering 227
Bionomics Raises USD9 Million in Private Placement of Shares 227
OpGen Raises USD5 Million in Private Placement of Shares 228
BeiGene Raises USD97.4 Million in Private Placement of Series A-2 Preferred Stock 229
Moderna Therapeutics Raises USD50 Million in Private Placement of Shares 230
BeiGene Raises USD74.5 Million in Private Placement of Series A Preferred Stock 231
Trius Therapeutics Completes Public Offering Of Shares For US$34 Million 232
Trius Therapeutics Completes Second Tranche Of Private Placement Of Shares For US$5 Million 233
VirtualScopics Completes First Tranche Of Private Placement Of Shares For US$3 Million 235
Trius Therapeutics Completes Over-allotment Option Of Underwritten Public Offering For US$52 Million 236
Debt Offering 238
Merck Plans to Raise Funds through Public Offering of Debt Securities 238
Merck Raises USD544 Million in Public Offering of 1.375% Notes Due 2036 239
Merck Raises USD544 Million in Public Offering of 0.5% Notes Due 2024 240
Merck Completes Public Offering of Notes Due 2020 for USD700 Million 241
Merck Completes Public Offering of Notes Due 2025 for USD2.5 Billion 243
Merck Completes Public Offering of Notes Due 2017 for USD300 Million 245
Merck Completes Public Offering of Notes Due 2045 for USD2 Billion 247
Merck Completes Public Offering of Notes Due 2020 for USD1.25 Billion 249
Merck Completes Public Offering of Notes Due 2022 for USD1.25 Billion 251
Merck Raises USD1.25 Billion in Public Offering of 1.875% Notes Due 2026 253
Merck Raises USD625 Million in Public Offering of 2.5% Notes Due 2034 255
Merck Raises USD1.25 Billion in Public Offering of 1.125% Notes Due 2021 257
Cubist Pharma Completes Private Placement Of Notes Due 2020 For US$450 Million 259
Cubist Pharma Completes Private Placement Of Notes Due 2018 For US$350 Million 260
Merck Completes Public Offering Of Notes Due 2016 For US$500 Million 261
Merck Completes Public Offering Of Notes Due 2016 For US$1 Billion 263
Merck Completes Public Offering Of Notes Due 2018 For US$1 Billion 265
Merck Completes Public Offering Of Notes Due 2023 For US$1.75 Billion 267
Merck Completes Public Offering Of Notes Due 2043 For US$1.25 Billion 269
Merck Completes Public Offering Of Floating Notes Due 2018 For US$1 Billion 271
BeiGene Raises USD3 Million in Private Placement of Notes 273
Merck Completes Public Offering Of Notes Due 2042 For US$500 Million 274
Merck Completes Public Offering Of 1.1% Notes Due 2018 For US$1 Billion 276
Merck Completes Public Offering Of Notes Due 2022 For US$1 Billion 278
Asset Transactions 280
Pharmaron Acquires Hoddesdon UK Site from Merck Sharpe & Dohme 280
Aralez Pharma Acquires US and Canadian rights to Zontivity from Merck 281
ANI Pharma Acquires Two NDAs from Merck Sharp & Dohme for USD75 Million 282
Piramal Enterprises Acquires Five OTC Brands from Organon India and MSD for USD14 Million 283
Mundipharma Ophthalmology Acquires Glaucoma Products Portfolio from Merck 284
Fareva Acquires La Vallee Manufacturing Site from Merck 285
Merial Acquires Manufacturing Facility from Merck 286
Santen Pharma Acquires Remaining Portfolio of Ophthalmology Products from Merck 287
Bayer Acquires Consumer Healthcare Business of Merck for USD14.2 Billion 289
AstraZeneca Exercises Option to Acquire Interest in Proton Pump Inhibitor Products from Merck 291
KBI Biopharma To Acquire Biologics Operations Of Merck 293
Amphastar Pharmaceuticals Acquires API manufacturing business of Merck 294
Oak Pharma Acquires Tafluprost Business from Merck 295
Akorn Acquires Rights to Zioptan from Merck Sharp & Dohme 296
Forest Labs To Acquire US Marketing Rights To Saphris From Merck Sharp & Dohme 297
Aspen Acquires Active Pharmaceutical Ingredients Business From Merck 298
Cerecor Acquires Rights To COMT Inhibitors From Merck 299
Kyorin Acquires Production Facility from MSD 301
Acquisition 302
Merck to Acquire Viralytics for USD394 Million 302
Merck Acquires Rigontec 304
Paratek Pharma May Sell Itself 306
Merck Acquires Afferent Pharma 308
Merck Acquires IOmet Pharma 309
Merck Acquires cCAM Biotherapeutics 310
Merck Acquires Cubist Pharma for USD9.5 Billion 311
Merck Acquires OncoEthix for USD375 Million 313
Merck Completes Acquisition of Idenix Pharma for USD3.9 Billion in cash 314
Alnylam Pharma Acquires Sirna Therapeutics From Merck 316
Akorn Acquires Inspire Pharma From Merck For US$53 Million 317
Cubist Pharma Completes Acquisition of Optimer Pharma for up to USD801 Million 319
Cubist Pharma Completes Acquisition Of Trius Therapeutics For Up To US$818 Million In A Tender Offer 321
Abbott, Johnson & Johnson And Sanofi Mull Individual Acquisition Of Bausch & Lomb 323
Merck Plans To Acquire Micro Labs, Maker Of Generic Drugs 325
Merck & Co Inc - Key Competitors 326
Merck & Co Inc - Key Employees 327
Merck & Co Inc - Locations And Subsidiaries 329
Head Office 329
Other Locations & Subsidiaries 329
Joint Venture 351
Recent Developments 353
Strategy And Business Planning 353
Nov 27, 2017: MSD announces plan to establish UK Discovery Centre in London 353
Jul 17, 2017: Governor Abbott Announces Merck IT Hub In Austin 354
Mar 02, 2017: Allergopharma Opens new Biopharmaceutical Production in Reinbek 355
Financial Announcements 356
May 01, 2018: Merck Announces First-Quarter 2018 Financial Results 356
Oct 27, 2017: Merck Announces Third-Quarter 2017 Financial Results 359
Jul 28, 2017: Merck Announces Second-Quarter 2017 Financial Results 361
May 02, 2017: Merck Announces First-Quarter 2017 Financial Results 364
Feb 02, 2017: Merck Announces Fourth-Quarter and Full-Year 2016 Financial Results 366
Corporate Communications 368
Jan 24, 2018: Merck Names Inge Thulin To Board Of Directors 368
Apr 10, 2017: Dr. John H. Noseworthy Nominated to Stand for Election to Merck Board of Directors 369
Mar 07, 2017: Merck reports positive data from Phase Ib trial of M1095 in psoriasis patients 370
Legal and Regulatory 371
Apr 25, 2018: Fish & Richardson Wins Federal Circuit Affirmance of Reversal of $200 Million Damages Against Gilead After Mercks "Unclean Hands" 371
Feb 19, 2018: Gilead wins reversal in $2.5 billion dispute with Merck 372
Feb 15, 2017: Mercks Wholly Owned Subsidiary Idenix Pharmaceuticals Awarded $2.54 Billion for Infringement of a Hepatitis C Drug Patent 373
Government and Public Interest 374
Dec 05, 2017: Bioethics International Releases the "Good Pharma Scorecard" in BMJ Open, Ranking the Top 20 Largest Pharmaceutical Companies on Clinical Trial Transparency 374
Oct 19, 2017: Merck Foundation Launches Five-Year Initiative to Improve Diabetes Care for Vulnerable and Underserved U.S. Communities 375
Mar 31, 2017: City Of Austin Announces Merck Economic Development Proposal 376
Feb 09, 2017: Merck Foundation Announces Six Program Grant Recipients for Alliance to Advance Patient-Centered Cancer Care 377
Jan 19, 2017: MSD for Mothers Commits $10 Million and Business Expertise to the Global Financing Facility to Help End Preventable Deaths of Mothers 378
Jan 18, 2017: Merck Foundation Grant Expands Project ECHO in Vietnam and India 379
Product News 380
11/21/2017: Medicure Reports Financial Results for Quarter Ended September 30, 2017 380
07/17/2017: Cardiome Announces Health Canada Approval of AGGRASTAT High Dose Bolus Regimen 382
07/13/2017: Aduro Announces Milestone Achieved Relating to Collaboration with Merck for Development of Anti-CD27 Antibody for the Treatment of Cancer 383
07/02/2018: Astellas Received Approval for Dafclir Tablets for the Treatment of Infectious Enteritis Caused by Clostridium difficile in Japan 384
05/30/2017: Merck Highlights Data on ZERBAXA at ASM Microbe 2017 385
04/24/2018: Global Study Published in JAMA Finds Treatment with Lonafarnib Extends Survival in Children with Progeria 386
04/19/2017: Merck to Present Data on Relebactam at ECCMID 2017 387
04/19/2017: Merck to Present Data on ZERBAXA at ECCMID 2017 388
04/02/2018: Eiger BioPharmaceuticals to Participate in Conferences in April 389
Product Approvals 390
Jan 23, 2018: Cardiome Announces Expanded Label for Aggrastat in China Including New STEMI Indication and High Dose Bolus Regimen 390
Jul 31, 2017: Astellas Submits Application for Approval of fidaxomicin for the Treatment of Infectious Enteritis Caused by Clostridium difficile in Japan 391
Clinical Trials 392
Jun 04, 2018: Eiger Announces HDV Phase 2 Program Oral Presentation and Investigator / Key Opinion Leader Reception for Planned HDV Phase 3 D-LIVR Study at Global Hepatitis Summit 2018 392
Apr 17, 2018: Eiger Announces Sub-Analysis of Phase 2 Results Demonstrating High Response Rates to All-Oral Lonafarnib-Ritonavir Regimen in Low Viral Load HDV-Infected Patients at The International Liver Congress 2018 393
Apr 17, 2018: Merck Announces First Phase Three Studies for PCV-15 (V114) Its Investigational Pneumococcal Disease Vaccine 394
Mar 21, 2018: Eiger BioPharmaceuticals Announces Positive Guidance Following FDA Meeting on Hepatitis Delta Virus Registration Program 395
Mar 05, 2018: Aduro Announces Milestone Achieved under Merck Collaboration for Initiation of Anti-CD27 Phase I Trial in Advanced Solid Tumors 396
Mar 05, 2018: Eiger Announces Abstracts and Presentations of LOWR HDV Program and Planned Registration Program at The International Liver Congress Meeting 397
Oct 23, 2017: Eiger Presents Data on Lonafarnib at the American Association for the Study of Liver Diseases Meeting 398
Oct 02, 2017: Eiger Announces Presentation on Lonafarnib at the American Association for the Study of Liver Diseases Meeting 399
Jul 25, 2017: Mercks Investigational NNRTI, Doravirine, Meets Primary Efficacy Endpoint of Non-Inferiority to Efavirenz, Both in Combination with Other Antiretroviral Agents, in Pivotal Phase 3 Trial for Treatment of HIV-1 Infection 400
Jul 06, 2017: Merck Announces Presentation on Doravirine at IAS 2017 402
Apr 21, 2017: Eiger Announces Additional Phase 2 Clinical Trial Results for Lonafarnib at The International Liver Congress 2017 403
Apr 06, 2017: Eiger Announces Abstracts and Presentations of LOWR HDV Program at the European Association for the Study of the Liver (EASL) Meeting 405
Feb 14, 2017: Mercks Doravirine, an Investigational Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI) for the Treatment of HIV-1 Infection, Met Primary Efficacy Endpoint in Pivotal Phase 3 Trial 406
Other Significant Developments 408
Nov 13, 2017: PeptiDream Announces 2 nd Milestone from Macrocyclic Peptide Drug Discovery Alliance with Merck & Co., Inc., Kenilworth, N.J., U.S.A 408
Oct 09, 2017: Johnson & Johnson investing $350M in EU biologics operation, adding 200 jobs 409
Jun 22, 2017: Merck and Premier Expand Collaboration to Address Chronic Care and Vaccination Rates 410
Jun 06, 2017: PeptiDream Announces First Milestone from Macrocyclic Peptide Drug Discovery Alliance with Merck 412
Feb 16, 2017: Mercks Fight Against Infectious Disease Goes Digital with Launch of ILUM Health Solutions 413
Appendix 414
Methodology 414
About GlobalData 414
Contact Us 414
Disclaimer 414

List Of Tables

List of Tables
Merck & Co Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Merck & Co Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 15
Merck & Co Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 16
Merck & Co Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 17
Merck & Co Inc, Deals By Therapy Area, 2012 to YTD 2018 18
Merck & Co Inc, Medical Devices Deals, 2012 to YTD 2018 20
Merck & Co Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 21
Hypermarcas To Sell Rights To Manufacture Medicines To MSD Brazil Investments For US$31 Million 34
Moderna Therapeutics Raises USD125 Million in Series H Preferred Equity Financing 35
Just Biotherapeutics Raises USD14 Million in Series A2 Financing 36
Just Biotherapeutics Raises USD15 Million in Series A Financing Round 38
RaNA Therapeutics Raises USD55 Million in series B Financing 39
Afferent Pharma Raises USD55 Million in Series C Financing 40
Gladius Pharma Raises USD3.3 Million in Series A Financing 41
NGM Biopharma Raises USD106 Million in Series E Financing 42
EnGene Raises USD11 Million in Series B Venture Financing 43
OsteoQC Raises Funds in Venture Financing 44
AdvanDx Raises US$12 Million In Series B-1 Venture Financing 45
HTG Molecular Diagnostics Raises Funds Through Extended Series E Financing 46
OncoEthix Raises US$19 Million In Series B Financing 47
Aviir Raises US$20 Million In Venture Financing 49
Afferent Pharmaceuticals Secures USD5 Million in Venture Funding Round 51
cCAM Biotherapeutics Raises US$6 Million In Series A Financing 52
Afferent Pharmaceuticals Secures USD5 Million in Venture Funding 53
Antigen Express Enters into Agreement with Merck for KEYTRUDA 54
CogState Enters Into Licensing Agreement With Merck Canada For Cognition Test 55
4D pharma Enters into Agreement with Merck 56
MSD Enters into Distribution Agreement with Kyorin Pharma 57
IO Biotech Enters into Clinical Trial Collaboration Agreement with Merck 58
Immutep Enters into Clinical Trial Collaboration and Supply Agreement with Merck 59
Eisai Enters into Co-Development and Co-Commercialization Agreement with Merck 60
Merck to Enter into Agreement with Schneider Electric 61
PharmAbcine Enters into Agreement with Merck 62
Parkinsons Institute and Clinical Center Enters into Agreement with Merck 63
Grunenthal Enters into Distribution Agreement with Merck 64
Astellas Pharma Enters into Co-Promotion Agreement with MSD 65
Aeglea BioTherapeutics Enters into Agreement with Merck 66
SELLAS Life Sciences Enters into Clinical Trial Agreement with Merck 67
Eisai Enters into Agreement with Merck for Eribulin 68
Eisai Enters into Agreement with Merck 69
AstraZeneca Enters into Agreement with Merck 70
Invenra Enters into Agreement With Merck 71
PDS Biotech Enters into Agreement with Merck 72
Leap Therapeutics Enters into Agreement with Merck International 73
Aduro Biotech Expands Agreement with Merck 74
OncoSec Medical Enters into Agreement with Merck Sharp & Dohme 75
Array BioPharma Enters into Agreement with Merck 76
Atara Biotherapeutics Enters into Agreement with Merck 77
HitGen Enters into Agreement with Merck 78
BerGenBio Enters into Agreement with Merck 79
Stratophase Enters into Agreement with Merck 80
CMIC Enters into Agreement with MSD for Diazoxide 81
Ramot at Tel Aviv University Enters into Research Agreement with Merck 82
NOXXON Pharma Enters into Agreement with Merck 83
Natrix Separations Enters into Co-Development Agreement with Merck and Sanofi 84
Proteros biostructures Enters into Agreement with Merck Sharp & Dohme 85
Genexine Enters into Clinical Research Agreement with Merck 86
Adaptimmune Therapeutics Enters into Clinical Trial Agreement with Merck for Keytruda 87
Merck Sharp & Dohme, Verastem and Cancer Research UK Enter into Agreement 88
Merck Enters into Distribution Agreement with JenKem Tech 89
MSD Enters into Agreement with Kyorin Pharma 90
Agency for Science, Technology and Research Enters into Agreement with Merck 91
Menarini Asia-Pacific Enters into Agreement with Merck 92
Innovative Targeting Solutions Enters into Research Agreement with Merck 93
Fujifilm Diosynth Biotech Partners with Merck 94
Merck Enters into Co-Promotion Agreement with Taiho Pharma for Pembrolizumab 95
Myriad Genetics Enters into Research Agreement with Tesaro and Merck 96
Daiichi Sankyo Enters into Co-Marketing Agreement with Merck 97
ImmunoGen Enters into Research Agreement with Merck 98
Merck Enters into Agreement with AbCellera Biologics 99
Affimed Enters into Research Agreement with Merck 100
BioLineRx Enters into Agreement with Merck 101
Quartet Medicine Enters into Agreement with Merck 102
Complix Expands Agreement with Merck 103
Eli Lilly Expands its Agreement with Merck 104
Merck Enters into Agreement with Akeso Biopharma 105
Amgen and Merck Enter into Agreement 106
Viralytics Enters into Agreement with Merck 107
GlaxoSmithKline Partners with Merck 108
Synthace Enters into Agreement with Merck 109
MacroGenics Enters into Agreement with Merck 110
Incyte Extends Partnership with Merck 111
Proteros Enters Into an Agreement with Merck Sharp and Dohme 112
Merck Enters into Agreement with OBI Pharma 113
Merck Enters into Agreement with DNAtrix 114
Merck Enters into Research Agreement with University of Texas MD Anderson Cancer Center 115
Immune Design Enters into Clinical Collaboration Agreement with Merck 116
Laboratorios Farmaceuticos Rovi Enters into Co-Marketing Agreement with Merck Sharp & Dohme for Orvatez 117
Plexxikon Enters into Agreement with Merck 118
PeptiDream Enters into Peptide Discovery Agreement with Merck 119
Organovo Enters into Research Agreement with Merck Sharp & Dohme 120
Syndax Pharma Expands its Agreement with Merck 121
Ablynx Extends Agreement with Merck to Develop Therapeutic Nanobody Candidates 122
NGM Biopharma Enters into R&D Agreement with Merck for Novel Biologic Therapeutics 123
Merck Expands Agreement with Eli Lilly 124
Enumeral Biomedical Amends Agreement with Merck Sharp & Dohme 125
Kyorin Pharma Amends Co-Marketing Agreement with MSD 126
Bind Therapeutics Enters into R&D Agreement with Merck 127
Advaxis Enters into Agreement with Merck 128
Bayer Enters Into Agreement With Merck For Soluble Guanylate Cyclase Modulators 129
Ferring Pharma And Merck Enter Into Agreement With World Health Organization For Anti-Bleeding Drug 130
Merck Enters Into Co-Development Agreement With Samsung Bioepis For MK-1293 131
Hanmi Pharma Enters into Co-promotion Agreement with Merck Sharp & Dohme Korea 132
Dako Enters Into Co-Development Agreement With Merck 133
Astellas Pharma Enters Into Co-Promotion Agreement With MSD For Ipragliflozin 134
Avanir Pharma Enters Into Agreement With Merck To Promote Diabetes Drugs 135
Optimer Pharma Extends Co-Promotion Agreement With Cubist Pharma For Dificid 137
Abide Therapeutics Enters Into Co-Development Agreement With Merck 138
Merck Enters Into Co-Development Agreement With Pfizer For Ertugliflozin 139
Cardiome Pharma Enters Into Co-Marketing Agreement With Merck For Brinavess 140
Lycera Enters Into Research Agreement With Merck To Develop Novel Treatments For Autoimmune Diseases 141
Adimab Expands Collaboration With Merck To Discover Human Antibody Candidates 142
Heptares Enters Into Research Agreement With Cubist Pharma For New Medicines Targeting GPCRs 143
ActoGeniX Enters Into Research Agreement With Merck 144
TPP Global Development Enters Into Agreement With Sprint Biosciences To Develop Choline Kinase Inhibitors 145
Ablynx Enters Into Agreement With Merck To Develop Therapeutic Nanobody Candidates 146
ALK Enters Into Co-Promotion Agreement With MSD For Grazax 147
Redbiotec Extends Drug Discovery Agreement With Merck 149
Merck Forms Joint Venture With Supera Farma Laboratorios 150
MSD Enters Into Distribution Agreement With Julphar 151
AstraZeneca Amends Co-Development Agreement With Merck For Nexium And Prilosec 152
Fundacion Medina Enters Into Research Agreement With Cubist Pharma 153
Trevena Enters Into Research Agreement With Merck For Biased Ligand Molecules 154
MSD India Plans Co-Marketing Agreement For Diabetes Drugs 155
Prokaryotics Enters into Licensing Agreement with Merck 156
Merck Enters into Licensing Agreement with Institute of Cancer Research and Cancer Research UK 157
Merck Enters into Licensing Agreement with Cue Biopharma 158
Dongwha Pharm Enters into Licensing Agreement with Merck 159
Merck Enters into Licensing And Option Agreement with AIMM Therapeutics 160
Urovant Sciences Enters into Licensing Agreement with Merck Sharp & Dohme 161
Merck Enters into Licensing Agreement with Teijin Pharma 162
Kyorin Pharma Enters into Licensing Agreement with Merck 163
Merck Enters into Licensing Agreement with Bristol-Myers Squibb and Ono Pharma 164
Merck Expands Licensing Agreement with Moderna Therapeutics 166
Merck Enters into Licensing Agreement with Harvard University 168
Merck Enters into Licensing Agreement with AureoGen Biosciences 169
Merck Enters into Licensing Agreement with Cancer Research Technology 170
Adimab Enters into Licensing Agreement with Merck 171
Merck Enters into Licensing Agreement with Selvita 172
Merck Enters into Licensing Agreement with Codexis for CodeEvolver Platform Technology 173
Allergan Enters into Licensing Agreement with Merck 175
Merck Extends Licensing Agreement with Agenus 176
Arvinas Enters into Licensing Agreement with Merck 177
Moderna Therapeutics Amends Terms of Licensing Agreement with Merck 178
Merck Enters into Licensing Agreement with BioNovion 179
Zymeworks Extends Licensing Agreement with Merck 180
Merck Enters into Licensing Agreement with NewLink Genetics 181
Euroscreen Enters into Licensing Agreement with Merck 183
Sun Pharma Enters into Licensing Agreement with Merck 184
Kyorin Pharma Enters into Licensing Agreement with Merck 185
Bionomics Enters into Licensing Agreement with Merck for BNC375 186
Agenus Enters into Licensing Agreement with Merck for Checkpoint Antibody-based Cancer Immunotherapies 187
Gulf Pharma Enters into Licensing Agreement with MSD 188
Gulf Pharmaceutical Industries (Julphar) Enters into Licensing Agreement with Merck 189
NanoBio Enters Into Licensing Agreement With Merck 190
Merck Expands Licensing Agreement with Ablynx 191
ARMO Biosciences Enters into Licensing Agreement with Merck 193
Bionomics Extends Licensing Agreement with Merck 194
Xencor Enters Into Licensing Agreement With Merck 195
Cerecor Enters Into Licensing Agreement With Merck For MK-0657 196
Meiji Seika Pharma Enters into Licensing Agreement with MSD 197
Merck Enters into Licensing Agreement with Ra Pharma 198
Cubist Pharma Enters Into Licensing Agreement With Astellas Pharma For Ceftolozane 200
Microbiotix Enters Into Licensing Agreement With Merck For MBX-700 And MBX-701 201
Menlo Therapeutics Enters into Licensing Agreement with Merck 202
Merck Enters Into Licensing Agreement With GE Healthcare For Flutemetamol 203
Theravance Enters Into Licensing Agreement With Merck For Cardiovascular Therapeutic Candidates 204
Merck Enters Into Licensing Agreement With AiCuris For Investigational Portfolio Targeting Human Cytomegalovirus 205
MultiVir Enters into Licensing Agreement with Merck Sharp & Dohme 207
R-Pharm Enters Into Licensing Agreement With Merck For Narlaprevir 208
Ambrx Enters Into Licensing Agreement With Merck For Site Specific Protein Medicinal Chemistry Technology 209
Tesaro Enters Into Licensing Agreement With Merck Sharp & Dohme For Cancer Drug 210
Merck Enters into Licensing Agreement with Medicines Patent Pool 211
EnWave Enters into Licensing Agreement with Merck 212
Cipla Enters Into Licensing Agreement With MSD Pharma For Raltegravir 213
Polyplus-transfection Enters Into Licensing Agreement With Merck 215
AstraZeneca Enters Into Licensing Agreement With Merck For MK-1775 216
Merck Enters Into Licensing Agreement With Lupin 218
Hawaii Biotech Enters Into Licensing Agreement With Merck For West Nile Vaccine Technology 219
Acerta Pharma Enters into Licensing Agreement with Merck Sharp & Dohme 220
Netherlands Translational Research Center Enters Into Licensing Agreement With Merck 221
Delphi Genetics Enters Into Licensing Agreement With Merck For StabyExpress Technology 222
Merck Enters Into Licensing Agreement With Yamasa For EFdA 223
Merck Enters Into Licensing Agreement With Numerate For In Silico Drug Design Technology 224
Merck Extends Licensing Agreement with Codexis 225
Merck Enters Into Licensing Agreement With Protein Sciences For expresSF+ Insect Cell Technology 226
Bionomics Raises USD9 Million in Private Placement of Shares 227
OpGen Raises USD5 Million in Private Placement of Shares 228
BeiGene Raises USD97.4 Million in Private Placement of Series A-2 Preferred Stock 229
Moderna Therapeutics Raises USD50 Million in Private Placement of Shares 230
BeiGene Raises USD74.5 Million in Private Placement of Series A Preferred Stock 231
Trius Therapeutics Completes Public Offering Of Shares For US$34 Million 232
Trius Therapeutics Completes Second Tranche Of Private Placement Of Shares For US$5 Million 233
VirtualScopics Completes First Tranche Of Private Placement Of Shares For US$3 Million 235
Trius Therapeutics Completes Over-allotment Option Of Underwritten Public Offering For US$52 Million 236
Merck Plans to Raise Funds through Public Offering of Debt Securities 238
Merck Raises USD544 Million in Public Offering of 1.375% Notes Due 2036 239
Merck Raises USD544 Million in Public Offering of 0.5% Notes Due 2024 240
Merck Completes Public Offering of Notes Due 2020 for USD700 Million 241
Merck Completes Public Offering of Notes Due 2025 for USD2.5 Billion 243
Merck Completes Public Offering of Notes Due 2017 for USD300 Million 245
Merck Completes Public Offering of Notes Due 2045 for USD2 Billion 247
Merck Completes Public Offering of Notes Due 2020 for USD1.25 Billion 249
Merck Completes Public Offering of Notes Due 2022 for USD1.25 Billion 251
Merck Raises USD1.25 Billion in Public Offering of 1.875% Notes Due 2026 253
Merck Raises USD625 Million in Public Offering of 2.5% Notes Due 2034 255
Merck Raises USD1.25 Billion in Public Offering of 1.125% Notes Due 2021 257
Cubist Pharma Completes Private Placement Of Notes Due 2020 For US$450 Million 259
Cubist Pharma Completes Private Placement Of Notes Due 2018 For US$350 Million 260
Merck Completes Public Offering Of Notes Due 2016 For US$500 Million 261
Merck Completes Public Offering Of Notes Due 2016 For US$1 Billion 263
Merck Completes Public Offering Of Notes Due 2018 For US$1 Billion 265
Merck Completes Public Offering Of Notes Due 2023 For US$1.75 Billion 267
Merck Completes Public Offering Of Notes Due 2043 For US$1.25 Billion 269
Merck Completes Public Offering Of Floating Notes Due 2018 For US$1 Billion 271
BeiGene Raises USD3 Million in Private Placement of Notes 273
Merck Completes Public Offering Of Notes Due 2042 For US$500 Million 274
Merck Completes Public Offering Of 1.1% Notes Due 2018 For US$1 Billion 276
Merck Completes Public Offering Of Notes Due 2022 For US$1 Billion 278
Pharmaron Acquires Hoddesdon UK Site from Merck Sharpe & Dohme 280
Aralez Pharma Acquires US and Canadian rights to Zontivity from Merck 281
ANI Pharma Acquires Two NDAs from Merck Sharp & Dohme for USD75 Million 282
Piramal Enterprises Acquires Five OTC Brands from Organon India and MSD for USD14 Million 283
Mundipharma Ophthalmology Acquires Glaucoma Products Portfolio from Merck 284
Fareva Acquires La Vallee Manufacturing Site from Merck 285
Merial Acquires Manufacturing Facility from Merck 286
Santen Pharma Acquires Remaining Portfolio of Ophthalmology Products from Merck 287
Bayer Acquires Consumer Healthcare Business of Merck for USD14.2 Billion 289
AstraZeneca Exercises Option to Acquire Interest in Proton Pump Inhibitor Products from Merck 291
KBI Biopharma To Acquire Biologics Operations Of Merck 293
Amphastar Pharmaceuticals Acquires API manufacturing business of Merck 294
Oak Pharma Acquires Tafluprost Business from Merck 295
Akorn Acquires Rights to Zioptan from Merck Sharp & Dohme 296
Forest Labs To Acquire US Marketing Rights To Saphris From Merck Sharp & Dohme 297
Aspen Acquires Active Pharmaceutical Ingredients Business From Merck 298
Cerecor Acquires Rights To COMT Inhibitors From Merck 299
Kyorin Acquires Production Facility from MSD 301
Merck to Acquire Viralytics for USD394 Million 302
Merck Acquires Rigontec 304
Paratek Pharma May Sell Itself 306
Merck Acquires Afferent Pharma 308
Merck Acquires IOmet Pharma 309
Merck Acquires cCAM Biotherapeutics 310
Merck Acquires Cubist Pharma for USD9.5 Billion 311
Merck Acquires OncoEthix for USD375 Million 313
Merck Completes Acquisition of Idenix Pharma for USD3.9 Billion in cash 314
Alnylam Pharma Acquires Sirna Therapeutics From Merck 316
Akorn Acquires Inspire Pharma From Merck For US$53 Million 317
Cubist Pharma Completes Acquisition of Optimer Pharma for up to USD801 Million 319
Cubist Pharma Completes Acquisition Of Trius Therapeutics For Up To US$818 Million In A Tender Offer 321
Abbott, Johnson & Johnson And Sanofi Mull Individual Acquisition Of Bausch & Lomb 323
Merck Plans To Acquire Micro Labs, Maker Of Generic Drugs 325
Merck & Co Inc, Key Competitors 326
Merck & Co Inc, Key Employees 327
Merck & Co Inc, Subsidiaries 329
Merck & Co Inc, Joint Venture 351

List Of Figures

List of Figures
Merck & Co Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Merck & Co Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Merck & Co Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Merck & Co Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Merck & Co Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 15
Merck & Co Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 16
Merck & Co Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 17
Merck & Co Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 18
Merck & Co Inc, Medical Devices Deals, 2012 to YTD 2018 20

Merck KGaA (MRK) - Pharmaceuticals and Healthcare - Deals and Alliances Profile

Merck KGaA (Merck), a subsidiary of E. Merck KG, is a pharmaceutical and chemical company. It discovers, develops and manufactures prescription drugs to treat cancer, multiple sclerosis, and infertility and

USD 250 View Report

Merck: Performance, Capabilities, Goals and Strategies in the Global Pharmaceutical Market

This report is part of the Competitive Analysis Series prepared by LeadingMarketResearch.com to help current suppliers and potential market entrants realistically assess their financial, technological and marketing capabilities in relation

USD 950 View Report

Merafe Resources Ltd - Strategy, SWOT and Corporate Finance Report

Merafe Resources Ltd - Strategy, SWOT and Corporate Finance ReportMerafe Resources Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report

USD 175 View Report

Hamburg Commercial Bank - Strategy, SWOT and Corporate Finance Report

Hamburg Commercial Bank - Strategy, SWOT and Corporate Finance ReportHamburg Commercial Bank - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report

USD 175 View Report

Fill The Form For Sample Request

Note : * Kindly provide us with your company id and get the sample reports at the earliest.

There is no Reviews available